Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Theravance Biopharma
Its shares trade under the ticker TBPH. It has been listed since 16 May 2014. In the fiscal year to 31 December 2025, it reported revenue of $107.5m and net income of $105.9m. At that date it held total assets of $485.6m and shareholders' equity of $296.7m.
Theravance Biopharma, Inc. operates as a biopharmaceutical company. The company is headquartered in George Town, Grand Cayman. The company went IPO on 2014-05-16. The firm is engaged in creating medicines for patients suffering from serious illness. The firm operates in the segment of discovery (research), development and commercialization of human therapeutics. The firm's pipeline of internally discovered product candidates includes medicines to address the unmet needs of patients being treated for serious conditions primarily in the acute care setting. Its commercial product VIBATIV (telavancin) is a once-daily dual-mechanism antibiotic approved in the United States and Europe for certain difficult-to-treat infections. Its Revefenacin (TD-4208) is a long-acting muscarinic antagonist (LAMA) being developed as a nebulized treatment for chronic obstructive pulmonary disease. Its neprilysin (NEP) inhibitor program is designed to develop selective NEP inhibitors for the treatment of a range of cardiovascular and renal diseases.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Pharmaceuticals
- Listed since
- 16 May 2014
- Employees
- 90
- Website
- theravance.com ↗
- Head office
- UGLAND HOUSE, SOUTH CHURCH STREET, GEORGE TOWN, GRAND CAYMAN, CA, KY1-1104
- Incorporated in
- CA
- Classification
- Pharmaceutical Preparations
- Filer status
- Non-accelerated filer<br>Smaller reporting company
Leadership
Pay as last reported
- Ms. Susannah GrayIndependent Chairman of the Board$301,413
- Mr. Rick WinninghamChief Executive Officer, Director, since 2013$4.0m
- Mr. Aziz SawafChief Financial Officer, Senior Vice President$1.5m
- Mr. Brett GrimaudSenior Vice President, General Counsel, Secretary$1.5m
- Ms. Rhonda FarnumSenior Vice President - Commercial and Medical Affairs, Chief Business Officer$942,806
- Dr. Aine MillerSenior Vice President - Development and Head of Ireland Office
- Dr. Laurie AlsupIndependent Director$294,329
- Mr. Eran BroshyIndependent Director$305,829
- Mr. Jeremy GrantIndependent Director$294,079
- Mr. James KellyIndependent Director$58,000
- Mr. Dean MitchellIndependent Director$315,639
- Mr. Donal O'ConnorIndependent Director$308,947
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 54
- Environment
- 62
- Social
- 27
- Governance
- 74
- Carbon reduction policy
- No
- Human rights policy
- No
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Theravance Biopharma Inc has several strengths that contribute to its competitive position in the biopharmaceutical industry. Firstly, the company has a strong portfolio of innovative drugs and therapies with high growth potential. This allows them to cater to a diverse range of medical conditions and provides a competitive edge in the market. Secondly, Theravance Biopharma Inc boasts a talented team of researchers and scientists who are dedicated to discovering and developing new drugs. Their expertise and commitment to innovation enable the company to stay at the forefront of medical advancements and deliver groundbreaking treatments to patients. Additionally, Theravance Biopharma Inc has established strategic partnerships and collaborations with other pharmaceutical companies, enhancing their capabilities and expanding their reach. These alliances enable the company to leverage shared resources, expertise, and market access, resulting in increased market share and revenue growth.
Weaknesses
- Despite its strengths, Theravance Biopharma Inc also faces certain weaknesses that could hinder its growth and profitability. One key weakness is the heavy reliance on a limited number of drugs for the majority of its revenue. This concentration risk exposes the company to significant financial vulnerabilities, as any setbacks or generic competition for these drugs could have a substantial impact on their financial performance. Additionally, Theravance Biopharma Inc faces challenges related to the lengthy and expensive drug development and approval process. This can result in delays in bringing new products to market and increase research and development costs. Such factors may limit the company's ability to rapidly expand its product portfolio and capitalize on emerging market opportunities.
Opportunities
- Theravance Biopharma Inc operates in an industry that offers several opportunities for growth and expansion. Firstly, the increasing prevalence of chronic diseases and the aging global population create a growing demand for effective therapies. This presents Theravance Biopharma Inc with opportunities to develop and market new drugs to address unmet medical needs. Furthermore, advances in technology and genomics offer potential for personalized medicine and targeted therapies. Theravance Biopharma Inc can leverage these advancements to develop tailored treatments that deliver better patient outcomes and capture a significant market share.
Threats
- Theravance Biopharma Inc faces various external threats that can impact its operations and market position. One significant threat is the intense competition within the biopharmaceutical industry. The presence of established giants and emerging biotech companies vying for market share poses challenges in terms of pricing pressures, market access, and retaining talented individuals. Additionally, regulatory and compliance requirements, along with the complex nature of drug development, pose threats to Theravance Biopharma Inc. These factors can contribute to delays in product approvals, increased costs, and legal and reputational risks.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.